GCT1184-04/GOG3134 A Randomized, Open-label, Phase 3 study of Rinatabart Sesutecan (Rina-S) plus Standard of Care versus Standard of Care as Maintenance Treatment after 2L Platinum-based Doublet Chemotherapy in Participants with Recurrent Platinum-sensitive Ovarian Cancer (PSOC)

by Mary Beth Wilwerding | Sep 2, 2026

MK2870-022/GOG3103 A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as First-line Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1

by Mary Beth Wilwerding | Sep 2, 2026

GOG-3134 A Randomized, Open-label, Phase 3 study of Rinatabart Sesutecan (Rina-S) plus Standard of Care versus Standard of Care as Maintenance Treatment after 2L Platinum-based Doublet Chemotherapy in Participants with Recurrent Platinum-sensitive Ovarian Cancer (PSOC)

by Mary Beth Wilwerding | Aug 19, 2026

GY032 A PHASE II STUDY OF TAILORED ADJUVANT THERAPY IN POLE-MUTATED AND p53-WILDTYPE/NSMP EARLY-STAGE ENDOMETRIAL CANCER (RAINBO BLUE & TAPER)

by Mary Beth Wilwerding | Aug 19, 2026

GY026 Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (Herceptin HYLECTA) or Pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma

by Mary Beth Wilwerding | Aug 19, 2026